.png)
Hemoglobinopathies Market by Type - Global Industry Analysis & Forecast to 2027
Published On : May 2022 Pages : 140 Category: Pharma & Healthcare Report Code : HC053543
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Hemoglobinopathies Market by Type (Sickle Cell Disease, Thalassemia, Other Hb variants diseases) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Hemoglobinopathies Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Hemoglobinopathies are a various arrangement of inborn blood infirmities that are a result of incongruities in the structure as well as amalgamation of hemoglobin. Hemoglobinopathies are hereditary single-quality issue that lead to an irregular structure of one of the globin chains of the hemoglobin atom, rendering it unfit to bring oxygen through the body, which prompts paleness or other medicinal anomalies.
Drivers and Restraints
Most medical coverage organizations, incorporating government programs in the United States also, Europe give protection inclusion to hemoglobinopathy treatment under the CPT code. This makes a good situation for the development of the worldwide hemoglobinopathy market. Different government activities are being completed for identification and the executives of hemoglobinopathy in high sickness predominance locales over the globe, giving a fillip to the worldwide hemoglobinopathy market.
Regional Insights
In 2017, North America was the biggest income producing locale with around USD 1.2 billion attributable to ascend in R&D speculations, better remuneration state, and nearness of top notch healthcare framework.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Novartis
- Emmaus Medical
- Medunik USA
- Bristol-Myers Squibb
- ApoPharma
- Sangamo Therapeutics, Inc.
- Sanofi
- Bluebird bio, Inc.
- Gamida Cell
- Alnylam Pharmaceuticals, Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Hemoglobinopathies Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o Sickle Cell Disease
o Thalassemia
o Other Hb variants diseases
· Hemoglobinopathies Market, By Key Players
o Novartis
o Emmaus Medical
o Medunik USA
o Bristol-Myers Squibb
o ApoPharma
o Sangamo Therapeutics, Inc.
o Sanofi
o Bluebird bio, Inc.
o Gamida Cell
o Alnylam Pharmaceuticals, Inc.
· Hemoglobinopathies Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Hemoglobinopathies Market, By Country
o U.S. Hemoglobinopathies Market
o Canada Hemoglobinopathies Market
o Mexico Hemoglobinopathies Market
o Europe
§ Europe Hemoglobinopathies Market, By Country
o Germany Hemoglobinopathies Market
o UK Hemoglobinopathies Market
o France Hemoglobinopathies Market
o Russia Hemoglobinopathies Market
o Italy Hemoglobinopathies Market
o Rest of Europe Hemoglobinopathies Market
o Asia-Pacific
§ Asia-Pacific Hemoglobinopathies Market, By Country
o China Hemoglobinopathies Market
o Japan Hemoglobinopathies Market
o South Korea Hemoglobinopathies Market
o India Hemoglobinopathies Market
o Southeast Asia Hemoglobinopathies Market
o Rest of Asia-Pacific Hemoglobinopathies Market
o South America
§ South America Hemoglobinopathies Market
o Brazil Hemoglobinopathies Market
o Argentina Hemoglobinopathies Market
o Columbia Hemoglobinopathies Market
o Rest of South America Hemoglobinopathies Market
o Middle East and Africa
§ Middle East and Africa Hemoglobinopathies Market
o Saudi Arabia Hemoglobinopathies Market
o UAE Hemoglobinopathies Market
o Egypt Hemoglobinopathies Market
o Nigeria Hemoglobinopathies Market
o South Africa Hemoglobinopathies Market
o Rest of MEA Hemoglobinopathies Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Hemoglobinopathies Market, By Type
5.1. Introduction
5.2. Global Hemoglobinopathies Revenue and Market Share by Type (2017-2027)
5.2.1. Global Hemoglobinopathies Revenue and Revenue Share by Type (2017-2027)
5.3. Sickle Cell Disease
5.3.1. Global Sickle Cell Disease Revenue and Growth Rate (2017-2027)
5.4. Thalassemia
5.4.1. Global Thalassemia Revenue and Growth Rate (2017-2027)
5.5. Other Hb variants diseases
5.5.1. Global Other Hb variants diseases Revenue and Growth Rate (2017-2027)
6. Hemoglobinopathies Market, By Region
6.1. Introduction
6.2. Global Hemoglobinopathies Revenue and Market Share by Regions
6.2.1. Global Hemoglobinopathies Revenue by Regions (2017-2027)
6.3. North America Hemoglobinopathies by Countries
6.3.1. North America Hemoglobinopathies Revenue and Growth Rate (2017-2027)
6.3.2. North America Hemoglobinopathies Revenue (Million USD) by Countries (2017-2027)
6.3.3. United States
6.3.3.1. United States Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.4. Canada
6.3.4.1. Canada Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.5. Mexico
6.3.5.1. Mexico Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.4. Europe Hemoglobinopathies by Countries
6.4.1. Europe Hemoglobinopathies Revenue and Growth Rate (2017-2027)
6.4.2. Europe Hemoglobinopathies Revenue (Million USD) by Countries (2017-2027)
6.4.3. Germany
6.4.3.1. Germany Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.4. France
6.4.4.1. France Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.5. UK
6.4.5.1. UK Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.6. Russia
6.4.6.1. Russia Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.7. Italy
6.4.7.1. Italy Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.5. Asia-Pacific Hemoglobinopathies by Countries
6.5.1. Asia-Pacific Hemoglobinopathies Revenue and Growth Rate (2017-2027)
6.5.2. Asia-Pacific Hemoglobinopathies Revenue (Million USD) by Countries (2017-2027)
6.5.3. China
6.5.3.1. China Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.4. Japan
6.5.4.1. Japan Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.5. Korea
6.5.5.1. Korea Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.6. India
6.5.6.1. India Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.6. South America Hemoglobinopathies by Countries
6.6.1. South America Hemoglobinopathies Revenue and Growth Rate (2017-2027)
6.6.2. South America Hemoglobinopathies Revenue (Million USD) by Countries (2017-2027)
6.6.3. Brazil
6.6.3.1. Brazil Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.4. Argentina
6.6.4.1. Argentina Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.5. Columbia
6.6.5.1. Columbia Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.7. Middle East and Africa Hemoglobinopathies by Countries
6.7.1. Middle East and Africa Hemoglobinopathies Revenue and Growth Rate (2017-2027)
6.7.2. Middle East and Africa Hemoglobinopathies Revenue (Million USD) by Countries (2017-2027)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.5. Egypt
6.7.5.1. Egypt Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.6. Nigeria
6.7.6.1. Nigeria Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.7. South Africa
6.7.7.1. South Africa Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.8. Turkey
6.7.8.1. Turkey Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
7. Company Profiles
7.1. Novartis
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Financial Overview
7.2. Emmaus Medical
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Financial Overview
7.3. Medunik USA
7.3.1. Business Overview
7.3.2. Service Portfolio
7.3.3. Strategic Developments
7.3.4. Financial Overview
7.4. Bristol-Myers Squibb
7.4.1. Business Overview
7.4.2. Service Portfolio
7.4.3. Strategic Developments
7.4.4. Financial Overview
7.5. ApoPharma
7.5.1. Business Overview
7.5.2. Service Portfolio
7.5.3. Strategic Developments
7.5.4. Financial Overview
7.6. Sangamo Therapeutics, Inc.
7.6.1. Business Overview
7.6.2. Service Portfolio
7.6.3. Strategic Developments
7.6.4. Financial Overview
7.7. Sanofi
7.7.1. Business Overview
7.7.2. Service Portfolio
7.7.3. Strategic Developments
7.7.4. Financial Overview
7.8. Bluebird bio, Inc.
7.8.1. Business Overview
7.8.2. Service Portfolio
7.8.3. Strategic Developments
7.8.4. Financial Overview
7.9. Gamida Cell
7.9.1. Business Overview
7.9.2. Service Portfolio
7.9.3. Strategic Developments
7.9.4. Financial Overview
7.10. Alnylam Pharmaceuticals, Inc.
7.10.1. Business Overview
7.10.2. Service Portfolio
7.10.3. Strategic Developments
7.10.4. Financial Overview
8. Global Hemoglobinopathies Market Competition, by Manufacturer
8.1. Global Hemoglobinopathies Financial Overview by Manufacturer (2017-2017)
8.2. Global Hemoglobinopathies Price By Region (2017-2017)
8.3. Top 5 Hemoglobinopathies Manufacturer Market Share
8.4. Market Competition Trend
9. Hemoglobinopathies Market Forecast (2017-2027)
9.1. Global Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Hemoglobinopathies Market Forecast by Regions (2017-2027)
9.2.1. North America Hemoglobinopathies Market Forecast (2017-2027)
9.2.1.1. United States Hemoglobinopathies Market Forecast (2017-2027)
9.2.1.2. Canada Hemoglobinopathies Market Forecast (2017-2027)
9.2.1.3. Mexico Hemoglobinopathies Market Forecast (2017-2027)
9.2.2. Europe Hemoglobinopathies Market Forecast (2017-2027)
9.2.2.1. Germany Hemoglobinopathies Market Forecast (2017-2027)
9.2.2.2. France Hemoglobinopathies Market Forecast (2017-2027)
9.2.2.3. UK Hemoglobinopathies Market Forecast (2017-2027)
9.2.2.4. Russia Hemoglobinopathies Market Forecast (2017-2027)
9.2.2.5. Italy Hemoglobinopathies Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Hemoglobinopathies Market Forecast (2017-2027)
9.2.3. Asia-Pacific Hemoglobinopathies Market Forecast (2017-2027)
9.2.3.1. China Hemoglobinopathies Market Forecast (2017-2027)
9.2.3.2. Japan Hemoglobinopathies Market Forecast (2017-2027)
9.2.3.3. Korea Hemoglobinopathies Market Forecast (2017-2027)
9.2.3.4. India Hemoglobinopathies Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Hemoglobinopathies Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Hemoglobinopathies Market Forecast (2017-2027)
9.2.4. South America Hemoglobinopathies Market Forecast (2017-2027)
9.2.4.1. Brazil Hemoglobinopathies Market Forecast (2017-2027)
9.2.4.2. Argentina Hemoglobinopathies Market Forecast (2017-2027)
9.2.4.3. Columbia Hemoglobinopathies Market Forecast (2017-2027)
9.2.4.4. Rest of South America Hemoglobinopathies Market Forecast (2017-2027)
9.2.5. Middle East and Africa Hemoglobinopathies Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Hemoglobinopathies Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Hemoglobinopathies Market Forecast (2017-2027)
9.2.5.3. Egypt Hemoglobinopathies Market Forecast (2017-2027)
9.2.5.4. Nigeria Hemoglobinopathies Market Forecast (2017-2027)
9.2.5.5. South Africa Hemoglobinopathies Market Forecast (2017-2027)
9.2.5.6. Turkey Hemoglobinopathies Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Hemoglobinopathies Market Forecast (2017-2027)
9.3. Hemoglobinopathies Market Forecast by Type (2017-2027)
9.3.1. Hemoglobinopathies Forecast by Type (2017-2027)
9.3.2. Hemoglobinopathies Market Share Forecast by Type (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Hemoglobinopathies Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Hemoglobinopathies Revenue and Revenue Share by Type (2017-2018)
Figure Global Sickle Cell Disease Revenue and Growth Rate (2017-2018)
Figure Global Thalassemia Revenue and Growth Rate (2017-2018)
Figure Global Other Hb variants diseases Revenue and Growth Rate (2017-2018)
Table Global Hemoglobinopathies Revenue by Regions (2017-2018)
Figure North America Hemoglobinopathies Growth Rate (2017-2018)
Figure North America Hemoglobinopathies Revenue and Growth Rate (2017-2018)
Figure North America Hemoglobinopathies by Countries (2017-2018)
Figure North America Hemoglobinopathies Revenue (Million USD) by Countries (2017-2018)
Figure United States Hemoglobinopathies Growth Rate (2017-2018)
Figure United States Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Hemoglobinopathies Growth Rate (2017-2018)
Figure Canada Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Hemoglobinopathies Growth Rate (2017-2018)
Figure Mexico Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Hemoglobinopathies Growth Rate (2017-2018)
Figure Europe Hemoglobinopathies Revenue and Growth Rate (2017-2018)
Figure Europe Hemoglobinopathies by Countries (2017-2018)
Figure Europe Hemoglobinopathies Revenue (Million USD) by Countries (2017-2018)
Figure Germany Hemoglobinopathies Growth Rate (2017-2018)
Figure Germany Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Hemoglobinopathies Growth Rate (2017-2018)
Figure France Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Hemoglobinopathies Growth Rate (2017-2018)
Figure UK Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Hemoglobinopathies Growth Rate (2017-2018)
Figure Russia Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Hemoglobinopathies Growth Rate (2017-2018)
Figure Italy Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Hemoglobinopathies Growth Rate (2017-2018)
Figure Rest of Europe Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Hemoglobinopathies Growth Rate (2017-2018)
Figure Asia-Pacific Hemoglobinopathies Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Hemoglobinopathies by Countries (2017-2018)
Figure Asia-Pacific Hemoglobinopathies Revenue (Million USD) by Countries (2017-2018)
Figure China Hemoglobinopathies Growth Rate (2017-2018)
Figure China Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Hemoglobinopathies Growth Rate (2017-2018)
Figure Japan Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Hemoglobinopathies Growth Rate (2017-2018)
Figure Korea Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Hemoglobinopathies Growth Rate (2017-2018)
Figure India Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Hemoglobinopathies Growth Rate (2017-2018)
Figure Southeast Asia Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Hemoglobinopathies Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Hemoglobinopathies Growth Rate (2017-2018)
Figure South America Hemoglobinopathies Revenue and Growth Rate (2017-2018)
Figure South America Hemoglobinopathies by Countries (2017-2018)
Figure South America Hemoglobinopathies Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Hemoglobinopathies Growth Rate (2017-2018)
Figure Brazil Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Hemoglobinopathies Growth Rate (2017-2018)
Figure Argentina Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Hemoglobinopathies Growth Rate (2017-2018)
Figure Columbia Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Hemoglobinopathies Growth Rate (2017-2018)
Figure Rest of South America Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Hemoglobinopathies Growth Rate (2017-2018)
Figure Middle East and Africa Hemoglobinopathies Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Hemoglobinopathies by Countries (2017-2018)
Figure Middle East and Africa Hemoglobinopathies Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Hemoglobinopathies Growth Rate (2017-2018)
Figure Saudi Arabia Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Hemoglobinopathies Growth Rate (2017-2018)
Figure United Arab Emirates Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Hemoglobinopathies Growth Rate (2017-2018)
Figure Egypt Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Hemoglobinopathies Growth Rate (2017-2018)
Figure Nigeria Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Hemoglobinopathies Growth Rate (2017-2018)
Figure South Africa Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Hemoglobinopathies Growth Rate (2017-2018)
Figure Turkey Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Hemoglobinopathies Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2017-2018)
Table Novartis Hemoglobinopathies Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Emmaus Medical Hemoglobinopathies Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Medunik USA Hemoglobinopathies Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bristol-Myers Squibb Hemoglobinopathies Price, Revenue, Gross Margin and Market Share (2017-2017)
Table ApoPharma Hemoglobinopathies Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sangamo Therapeutics, Inc. Hemoglobinopathies Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sanofi Hemoglobinopathies Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bluebird bio, Inc. Hemoglobinopathies Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Gamida Cell Hemoglobinopathies Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Alnylam Pharmaceuticals, Inc. Hemoglobinopathies Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Hemoglobinopathies Market Share by Manufacturer
Figure Global Hemoglobinopathies Revenue and Market Share by Manufacturer
Table Global Hemoglobinopathies Price by Region (2017-2017)
Figure Top 5 Hemoglobinopathies Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Hemoglobinopathies Revenue (Millions USD) and Growth Rate (2018-2025)
Table Hemoglobinopathies Market Forecast by Regions (2018-2025)
Figure North America Hemoglobinopathies Market Forecast (2018-2025)
Figure United States Hemoglobinopathies Market Forecast (2018-2025)
Figure Canada Hemoglobinopathies Market Forecast (2018-2025)
Figure Mexico Hemoglobinopathies Market Forecast (2018-2025)
Figure Europe Hemoglobinopathies Market Forecast (2018-2025)
Figure Germany Hemoglobinopathies Market Forecast (2018-2025)
Figure France Hemoglobinopathies Market Forecast (2018-2025)
Figure UK Hemoglobinopathies Market Forecast (2018-2025)
Figure Russia Hemoglobinopathies Market Forecast (2018-2025)
Figure Italy Hemoglobinopathies Market Forecast (2018-2025)
Figure Rest of Europe Hemoglobinopathies Market Forecast (2018-2025)
Figure Asia-Pacific Hemoglobinopathies Market Forecast (2018-2025)
Figure China Hemoglobinopathies Market Forecast (2018-2025)
Figure Japan Hemoglobinopathies Market Forecast (2018-2025)
Figure Korea Hemoglobinopathies Market Forecast (2018-2025)
Figure India Hemoglobinopathies Market Forecast (2018-2025)
Figure Southeast Asia Hemoglobinopathies Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Hemoglobinopathies Market Forecast (2018-2025)
Figure South America Hemoglobinopathies Market Forecast (2018-2025)
Figure Brazil Hemoglobinopathies Market Forecast (2018-2025)
Figure Argentina Hemoglobinopathies Market Forecast (2018-2025)
Figure Columbia Hemoglobinopathies Market Forecast (2018-2025)
Figure Rest of South America Hemoglobinopathies Market Forecast (2018-2025)
Figure Middle East and Africa Hemoglobinopathies Market Forecast (2018-2025)
Figure Saudi Arabia Hemoglobinopathies Market Forecast (2018-2025)
Figure United Arab Emirates Hemoglobinopathies Market Forecast (2018-2025)
Figure Egypt Hemoglobinopathies Market Forecast (2018-2025)
Figure Nigeria Hemoglobinopathies Market Forecast (2018-2025)
Figure South Africa Hemoglobinopathies Market Forecast (2018-2025)
Figure Turkey Hemoglobinopathies Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Hemoglobinopathies Market Forecast (2018-2025)
Figure Global Hemoglobinopathies Forecast by Type (2018-2025)
Figure Global Hemoglobinopathies Market Share Forecast by Type (2018-2025)
Figure Global Hemoglobinopathies Forecast by Type (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|